Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

T Cells Control Chemokine Secretion by Keratinocytes.

Rauschenberger T, Schmitt V, Azeem M, Klein-Hessling S, Murti K, Grän F, Goebeler M, Kerstan A, Klein M, Bopp T, Serfling E, Muhammad K.

Front Immunol. 2019 Aug 9;10:1917. doi: 10.3389/fimmu.2019.01917. eCollection 2019.

2.

The Transcription Factor NFATc1 Supports the Rejection of Heterotopic Heart Allografts.

Baur J, Otto C, Steger U, Klein-Hessling S, Muhammad K, Pusch T, Murti K, Wismer R, Germer CT, Klein I, Müller N, Serfling E, Avots A.

Front Immunol. 2018 Jun 12;9:1338. doi: 10.3389/fimmu.2018.01338. eCollection 2018.

3.

B cell development is critically dependent on NFATc1 activity.

Giampaolo S, Wójcik G, Klein-Hessling S, Serfling E, Patra AK.

Cell Mol Immunol. 2019 May;16(5):508-520. doi: 10.1038/s41423-018-0052-9. Epub 2018 Jun 15.

4.

NFAT-mediated defects in erythropoiesis cause anemia in Il2-/- mice.

Giampaolo S, Wójcik G, Klein-Hessling S, Serfling E, Patra AK.

Oncotarget. 2017 Dec 28;9(11):9632-9644. doi: 10.18632/oncotarget.23745. eCollection 2018 Feb 9.

5.

Induction of Short NFATc1/αA Isoform Interferes with Peripheral B Cell Differentiation.

Muhammad K, Rudolf R, Pham DAT, Klein-Hessling S, Takata K, Matsushita N, Ellenrieder V, Kondo E, Serfling E.

Front Immunol. 2018 Jan 24;9:32. doi: 10.3389/fimmu.2018.00032. eCollection 2018.

6.

Store-Operated Ca2+ Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming.

Vaeth M, Maus M, Klein-Hessling S, Freinkman E, Yang J, Eckstein M, Cameron S, Turvey SE, Serfling E, Berberich-Siebelt F, Possemato R, Feske S.

Immunity. 2017 Oct 17;47(4):664-679.e6. doi: 10.1016/j.immuni.2017.09.003. Epub 2017 Oct 11.

7.

NFATc1 controls the cytotoxicity of CD8+ T cells.

Klein-Hessling S, Muhammad K, Klein M, Pusch T, Rudolf R, Flöter J, Qureischi M, Beilhack A, Vaeth M, Kummerow C, Backes C, Schoppmeyer R, Hahn U, Hoth M, Bopp T, Berberich-Siebelt F, Patra A, Avots A, Müller N, Schulze A, Serfling E.

Nat Commun. 2017 Sep 11;8(1):511. doi: 10.1038/s41467-017-00612-6.

8.

Corrigendum: NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.

Alrefai H, Muhammad K, Rudolf R, Pham DAT, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E.

Nat Commun. 2016 Aug 2;7:12421. doi: 10.1038/ncomms12421. No abstract available.

9.

A threshold level of NFATc1 activity facilitates thymocyte differentiation and opposes notch-driven leukaemia development.

Klein-Hessling S, Rudolf R, Muhammad K, Knobeloch KP, Maqbool MA, Cauchy P, Andrau JC, Avots A, Talora C, Ellenrieder V, Screpanti I, Serfling E, Patra AK.

Nat Commun. 2016 Jun 17;7:11841. doi: 10.1038/ncomms11841.

10.

NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.

Alrefai H, Muhammad K, Rudolf R, Pham DA, Klein-Hessling S, Patra AK, Avots A, Bukur V, Sahin U, Tenzer S, Goebeler M, Kerstan A, Serfling E.

Nat Commun. 2016 May 25;7:11724. doi: 10.1038/ncomms11724. Erratum in: Nat Commun. 2016 Aug 02;7:12421.

11.

NF-κB factors control the induction of NFATc1 in B lymphocytes.

Muhammad K, Alrefai H, Marienfeld R, Pham DA, Murti K, Patra AK, Avots A, Bukur V, Sahin U, Kondo E, Klein-Hessling S, Serfling E.

Eur J Immunol. 2014 Nov;44(11):3392-402. doi: 10.1002/eji.201444756. Epub 2014 Sep 26.

12.

Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression.

Vaeth M, Müller G, Stauss D, Dietz L, Klein-Hessling S, Serfling E, Lipp M, Berberich I, Berberich-Siebelt F.

J Exp Med. 2014 Mar 10;211(3):545-61. doi: 10.1084/jem.20130604. Epub 2014 Mar 3.

13.

Architecture and expression of the nfatc1 gene in lymphocytes.

Rudolf R, Busch R, Patra AK, Muhammad K, Avots A, Andrau JC, Klein-Hessling S, Serfling E.

Front Immunol. 2014 Feb 3;5:21. doi: 10.3389/fimmu.2014.00021. eCollection 2014. Review.

14.

Immunosuppression by N-methyl-D-aspartate receptor antagonists is mediated through inhibition of Kv1.3 and KCa3.1 channels in T cells.

Kahlfuß S, Simma N, Mankiewicz J, Bose T, Lowinus T, Klein-Hessling S, Sprengel R, Schraven B, Heine M, Bommhardt U.

Mol Cell Biol. 2014 Mar;34(5):820-31. doi: 10.1128/MCB.01273-13. Epub 2013 Dec 16.

15.

NFATc1 induction in peripheral T and B lymphocytes.

Hock M, Vaeth M, Rudolf R, Patra AK, Pham DA, Muhammad K, Pusch T, Bopp T, Schmitt E, Rost R, Berberich-Siebelt F, Tyrsin D, Chuvpilo S, Avots A, Serfling E, Klein-Hessling S.

J Immunol. 2013 Mar 1;190(5):2345-53. doi: 10.4049/jimmunol.1201591. Epub 2013 Jan 30.

16.

NFATc1/αA: The other Face of NFAT Factors in Lymphocytes.

Serfling E, Avots A, Klein-Hessling S, Rudolf R, Vaeth M, Berberich-Siebelt F.

Cell Commun Signal. 2012 Jul 5;10(1):16. doi: 10.1186/1478-811X-10-16.

17.

NFATc1 affects mouse splenic B cell function by controlling the calcineurin--NFAT signaling network.

Bhattacharyya S, Deb J, Patra AK, Thuy Pham DA, Chen W, Vaeth M, Berberich-Siebelt F, Klein-Hessling S, Lamperti ED, Reifenberg K, Jellusova J, Schweizer A, Nitschke L, Leich E, Rosenwald A, Brunner C, Engelmann S, Bommhardt U, Avots A, Müller MR, Kondo E, Serfling E.

J Exp Med. 2011 Apr 11;208(4):823-39. doi: 10.1084/jem.20100945. Epub 2011 Apr 4.

18.

Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway.

Lu Y, Xiong Y, Huo Y, Han J, Yang X, Zhang R, Zhu DS, Klein-Hessling S, Li J, Zhang X, Han X, Li Y, Shen B, He Y, Shibuya M, Feng GS, Luo J.

Proc Natl Acad Sci U S A. 2011 Feb 15;108(7):2957-62. doi: 10.1073/pnas.1009395108. Epub 2011 Jan 31.

19.

Cyclic AMP-induced chromatin changes support the NFATc-mediated recruitment of GATA-3 to the interleukin 5 promoter.

Klein-Hessling S, Bopp T, Jha MK, Schmidt A, Miyatake S, Schmitt E, Serfling E.

J Biol Chem. 2008 Nov 7;283(45):31030-7. doi: 10.1074/jbc.M805929200. Epub 2008 Sep 4.

20.

Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling.

Akimzhanov A, Krenacs L, Schlegel T, Klein-Hessling S, Bagdi E, Stelkovics E, Kondo E, Chuvpilo S, Wilke P, Avots A, Gattenlöhner S, Müller-Hermelink HK, Palmetshofer A, Serfling E.

Am J Pathol. 2008 Jan;172(1):215-24. Epub 2007 Dec 21.

21.

Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression.

Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Heib V, Becker M, Kubach J, Schmitt S, Stoll S, Schild H, Staege MS, Stassen M, Jonuleit H, Schmitt E.

J Exp Med. 2007 Jun 11;204(6):1303-10. Epub 2007 May 14.

22.

Epigenetic control of the foxp3 locus in regulatory T cells.

Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J.

PLoS Biol. 2007 Feb;5(2):e38.

23.

Specific and redundant roles for NFAT transcription factors in the expression of mast cell-derived cytokines.

Klein M, Klein-Hessling S, Palmetshofer A, Serfling E, Tertilt C, Bopp T, Heib V, Becker M, Taube C, Schild H, Schmitt E, Stassen M.

J Immunol. 2006 Nov 15;177(10):6667-74.

24.

NFAT transcription factors in control of peripheral T cell tolerance.

Serfling E, Klein-Hessling S, Palmetshofer A, Bopp T, Stassen M, Schmitt E.

Eur J Immunol. 2006 Nov;36(11):2837-43. Review.

25.

p38 MAP kinase drives the expression of mast cell-derived IL-9 via activation of the transcription factor GATA-1.

Stassen M, Klein M, Becker M, Bopp T, Neudörfl C, Richter C, Heib V, Klein-Hessling S, Serfling E, Schild H, Schmitt E.

Mol Immunol. 2007 Feb;44(5):926-33. Epub 2006 May 2.

PMID:
16650898
26.

SUMOylation interferes with CCAAT/enhancer-binding protein beta-mediated c-myc repression, but not IL-4 activation in T cells.

Berberich-Siebelt F, Berberich I, Andrulis M, Santner-Nanan B, Jha MK, Klein-Hessling S, Schimpl A, Serfling E.

J Immunol. 2006 Apr 15;176(8):4843-51.

27.

NFAT and NF-kappaB factors-the distant relatives.

Serfling E, Berberich-Siebelt F, Avots A, Chuvpilo S, Klein-Hessling S, Jha MK, Kondo E, Pagel P, Schulze-Luehrmann J, Palmetshofer A.

Int J Biochem Cell Biol. 2004 Jul;36(7):1166-70. Review.

PMID:
15109564
28.

Protein kinase A regulates GATA-3-dependent activation of IL-5 gene expression in Th2 cells.

Klein-Hessling S, Jha MK, Santner-Nanan B, Berberich-Siebelt F, Baumruker T, Schimpl A, Serfling E.

J Immunol. 2003 Mar 15;170(6):2956-61.

29.

IL-9 and IL-13 production by activated mast cells is strongly enhanced in the presence of lipopolysaccharide: NF-kappa B is decisively involved in the expression of IL-9.

Stassen M, Müller C, Arnold M, Hültner L, Klein-Hessling S, Neudörfl C, Reineke T, Serfling E, Schmitt E.

J Immunol. 2001 Apr 1;166(7):4391-8.

30.

The role of NF-AT transcription factors in T cell activation and differentiation.

Serfling E, Berberich-Siebelt F, Chuvpilo S, Jankevics E, Klein-Hessling S, Twardzik T, Avots A.

Biochim Biophys Acta. 2000 Oct 20;1498(1):1-18. Review.

31.

C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells.

Berberich-Siebelt F, Klein-Hessling S, Hepping N, Santner-Nanan B, Lindemann D, Schimpl A, Berberich I, Serfling E.

Eur J Immunol. 2000 Sep;30(9):2576-85.

32.

A CD28-associated signaling pathway leading to cytokine gene transcription and T cell proliferation without TCR engagement.

Siefken R, Klein-Hessling S, Serfling E, Kurrle R, Schwinzer R.

J Immunol. 1998 Aug 15;161(4):1645-51.

33.

HMG I(Y) interferes with the DNA binding of NF-AT factors and the induction of the interleukin 4 promoter in T cells.

Klein-Hessling S, Schneider G, Heinfling A, Chuvpilo S, Serfling E.

Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15311-6.

34.

The inducible transcription factor NF-AT plays an important role in the activation of the murine interleukin-4 promoter.

Schneider G, Heinfling A, Klein-Hessling S, Schomberg C, Chuvpilo S, Serfling E.

Immunobiology. 1995 Jul;193(2-4):268-72. Review. No abstract available.

PMID:
8530154
35.

Octamer factors exert a dual effect on the IL-2 and IL-4 promoters.

Pfeuffer I, Klein-Hessling S, Heinfling A, Chuvpilo S, Escher C, Brabletz T, Hentsch B, Schwarzenbach H, Matthias P, Serfling E.

J Immunol. 1994 Dec 15;153(12):5572-85.

PMID:
7989759

Supplemental Content

Loading ...
Support Center